Mycobutin Oral Capsule 150Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • Weekly Ad

Mycobutin: Oral capsule (150mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file DrugItem_5587.JPG
Mycobutin 150mg Cap
Pfizer US Pharmaceuticals
Pill Identification: MYCOBUTIN Pharmacia & Upjohn 
Drug Image file DrugItem_20554.JPG
Rifabutin 150mg Capsule
Lupin Pharmaceuticals
Pill Identification: LU R01 
Drug Image file DrugItem_18222.JPG
Rifabutin 150mg Cap
Greenstone Ltd
Pill Identification: MYCOBUTIN PHARMACIA & UPJOHN 

What is this Medicine?

RIFABUTIN (RIF a byoo tin) is an antibiotic. It is used to prevent mycobacterium avium complex (MAC) in people with HIV infection. This medicine does not cure or prevent HIV. It will not work for colds, flu, or other viral infections.

Similar Generic Drugs : Rifabutin: Oral capsule (150mg)
In-Depth Information

Mycobutin 150mg Capsule

NDC: 000135301
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Mycobacterium Avium Complex (MAC) Prophylaxis

Sometimes used for but not FDA approved for the following conditions:
Tuberculosis Infection, Mycobacterium Avium Complex Infection, Tuberculosis Prophylaxis

Storage Information
Store at 77 degrees F; excursions permitted to 59-86 degrees F
Mycobutin 150mg Capsule
Drug Image file DrugItem_5587.JPG
Pfizer US Pharmaceuticals
Pill Identification: MYCOBUTIN Pharmacia & Upjohn 
Shape: capsule
Color: brown

Reported Side Effects for Mycobutin 150mg Capsule

Paresthesias Incidence:
<1.0%*
Severity: MILD
Onset: DELAYED
No White Blood Cells Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Liver Infection Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Yellow Skin Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Pancytopenia Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Convulsions Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Moschcowitz Syndrome Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Unable To Speak Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Breathing Difficulties Incidence:
<1.0%*
Severity: SEVERE
Onset: RAPID
Confusion Incidence:
<1.0%*
Severity: MODERATE
Onset: EARLY
Elevated Hepatic Enzymes Incidence:
<9.0%*
Severity: MODERATE
Onset: DELAYED
Low Lymphocytes Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Hemolysis Incidence:
<1.0%*
Severity: MODERATE
Onset: EARLY
Visual Impairment Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Shortness Of Breath Incidence:
<1.0%*
Severity: MODERATE
Onset: EARLY
Joint Pain Incidence:
<1.0%*
Severity: MILD
Onset: DELAYED
ST-T Wave Changes Incidence:
<1.0%*
Severity: MODERATE
Onset: RAPID
Eye Pain Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Pseudomembranous Colitis Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Skin Discoloration Incidence:
<1.0%*
Severity: MILD
Onset: DELAYED
Eye Inflammation Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Inability To Sleep Incidence:
1.0%*
Severity: MILD
Onset: EARLY
Vomiting Incidence:
1.0-3.0%*
Severity: MILD
Onset: EARLY
Weakness Incidence:
1.0%*
Severity: MILD
Onset: DELAYED
Eosinophilia Incidence:
1.0%*
Severity: MODERATE
Onset: DELAYED
Chest Pain Incidence:
1.0%*
Severity: MODERATE
Onset: EARLY
Decreased Appetite Incidence:
2.0%*
Severity: MILD
Onset: DELAYED
Fever Incidence:
2.0%*
Severity: MILD
Onset: EARLY
Gas Incidence:
2.0%*
Severity: MILD
Onset: EARLY
Muscle Pain Incidence:
2.0%*
Severity: MILD
Onset: EARLY
Upset Stomach Incidence:
3.0-6.0%*
Severity: MILD
Onset: EARLY
Belching Incidence:
3.0%*
Severity: MILD
Onset: EARLY
Metallic Taste Incidence:
3.0%*
Severity: MILD
Onset: EARLY
Headache Incidence:
3.0%*
Severity: MILD
Onset: EARLY
Upset Stomach Incidence:
3.0%*
Severity: MILD
Onset: EARLY
Loose Stools Incidence:
3.0%*
Severity: MILD
Onset: EARLY
Stomach Pain Incidence:
4.0%*
Severity: MILD
Onset: EARLY
Low Platelet Count Incidence:
5.0%*
Severity: MODERATE
Onset: DELAYED
Anemia Incidence:
6.0%*
Severity: MODERATE
Onset: DELAYED
Contact Lens Discoloration Incidence:
>10.0%*
Severity: MILD
Onset: DELAYED
Skin Rash Incidence:
11.0%*
Severity: MILD
Onset: EARLY
Low White Blood Cell Counts Incidence:
17.0%*
Severity: MODERATE
Onset: DELAYED
Low White Blood Cells Incidence:
25.0%*
Severity: MODERATE
Onset: DELAYED
Urine Discoloration Incidence:
>30.0%*
Severity: MILD
Onset: EARLY
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Daily Life Interactions for Mycobutin 150mg Capsule

Elements of your daily lifestyle may have an effect on the medications you are taking. Drug interactions can result in unwanted side effects, reduce the effectiveness of your medicine or possibly increase the action of a particular medicine.

Moderate Lifestyle Interaction
Marijuana and Mycobutin 150mg Capsule(Rifabutin)
Marijuana and Rifabutin(Rifabutin)
Rifabutin can theoretically increase the elimination of Marijuana, Medical from the body. The side effects profile of Marijuana, Medical may be altered if you take Rifabutin. You may feel drowsy or more tired. Do not drive or operate machinery until you know how these drugs affect you. Contact your health care provider immediately if you notice slurred speech, confusion, increases heart rate, or palpitations while taking Marijuana, Medical.
Pregnancy & Lactation Information
FIRST Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

SECOND Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

THIRD Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

Lactation

Compatible - This drug is generally safe to take by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Mycobutin

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5